OverviewChartTechnicalNewsTraderScreen

Ultragenyx Pharmaceutical Inc/  US90400D1081  /

NASDAQ
2024-04-19  10:00:00 PM Chg. -1.0100 Volume Bid10:37:16 PM Ask10:37:16 PM High Low
42.3700USD -2.33% 676,054
Turnover: 20.4 mill.		 42.3700Bid Size: 200 46.0400Ask Size: 100 43.9200 41.0700
GlobeNewswire 04-19 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 04-15 Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatm...
GlobeNewswire 04-15 Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
GlobeNewswire 04-12 Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients w...
GlobeNewswire 04-12 Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual ...
GlobeNewswire 04-03 Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Confer...
GlobeNewswire 03-27 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03-22 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 03-05 Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
GlobeNewswire 02-28 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
GlobeNewswire 02-27 Ultragenyx to Participate at Investor Conferences in March
GlobeNewswire 02-23 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 02-15 Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 02-08 Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corpo...
GlobeNewswire 02-06 Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Hep...
GlobeNewswire 02-05 Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treat...
GlobeNewswire 01-25 Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Stu...
GlobeNewswire 01-19 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 01-08 Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
GlobeNewswire 01-07 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Upda...
GlobeNewswire 01-04 Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Ad...
GlobeNewswire 01-03 Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Pati...
GlobeNewswire 01-02 Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-21 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2023-12-18 Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Ch...